CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - TSX:CPH - CA17253X1050 - Common Stock
14.79 CAD
+0.05 (+0.34%)
CPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 31 industry peers in the Pharmaceuticals industry. CPH scores excellent on profitability, but there are some minor concerns on its financial health. CPH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
CPH had positive earnings in the past year.
In the past year CPH had a positive cash flow from operations.
In the past 5 years CPH has always been profitable.
Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
CPH's Return On Assets of 7.97% is amongst the best of the industry. CPH outperforms 87.10% of its industry peers.
CPH has a Return On Equity of 11.10%. This is amongst the best in the industry. CPH outperforms 87.10% of its industry peers.
CPH has a Return On Invested Capital of 5.17%. This is amongst the best in the industry. CPH outperforms 80.65% of its industry peers.
CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 7.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROIC | 5.17% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
CPH has a better Profit Margin (25.52%) than 100.00% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
CPH's Operating Margin of 20.32% is amongst the best of the industry. CPH outperforms 90.32% of its industry peers.
In the last couple of years the Operating Margin of CPH has declined.
Looking at the Gross Margin, with a value of 73.79%, CPH belongs to the top of the industry, outperforming 93.55% of the companies in the same industry.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPH is still creating some value.
CPH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CPH has less shares outstanding
The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
CPH has an Altman-Z score of 5.11. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
CPH's Altman-Z score of 5.11 is amongst the best of the industry. CPH outperforms 93.55% of its industry peers.
CPH has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.23, CPH perfoms like the industry average, outperforming 51.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.11 |
ROIC/WACC0.65
WACC7.93%
2.3 Liquidity
A Current Ratio of 1.72 indicates that CPH should not have too much problems paying its short term obligations.
CPH's Current ratio of 1.72 is in line compared to the rest of the industry. CPH outperforms 45.16% of its industry peers.
A Quick Ratio of 1.41 indicates that CPH should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.41, CPH perfoms like the industry average, outperforming 51.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
CPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
Looking at the last year, CPH shows a very strong growth in Revenue. The Revenue has grown by 114.76%.
CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%83.33%
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
3.2 Future
CPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.16% yearly.
CPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.67% yearly.
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 22.75, the valuation of CPH can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of CPH indicates a rather cheap valuation: CPH is cheaper than 83.87% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.13. CPH is around the same levels.
With a Price/Forward Earnings ratio of 16.00, CPH is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 77.42% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.35. CPH is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.75 | ||
| Fwd PE | 16 |
4.2 Price Multiples
CPH's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.74 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has an outstanding profitability rating, which may justify a higher PE ratio.
CPH's earnings are expected to grow with 13.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.59
PEG (5Y)1.75
EPS Next 2Y19.46%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
CPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (11/4/2025, 7:00:00 PM)
14.79
+0.05 (+0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap374.48M
Revenue(TTM)47.59M
Net Income(TTM)12.14M
Analysts77.78
Price Target18.26 (23.46%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.48%
Min EPS beat(2)-7.18%
Max EPS beat(2)36.14%
EPS beat(4)1
Avg EPS beat(4)-25.25%
Min EPS beat(4)-92.76%
Max EPS beat(4)36.14%
EPS beat(8)5
Avg EPS beat(8)61.68%
EPS beat(12)9
Avg EPS beat(12)108.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-0.23%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)2.48%
Revenue beat(8)3
Avg Revenue beat(8)6.68%
Revenue beat(12)3
Avg Revenue beat(12)0.57%
Revenue beat(16)3
Avg Revenue beat(16)-2.32%
PT rev (1m)2.17%
PT rev (3m)11.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)-31.15%
EPS NY rev (3m)0.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.88%
Revenue NY rev (1m)4.34%
Revenue NY rev (3m)1.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.75 | ||
| Fwd PE | 16 | ||
| P/S | 5.59 | ||
| P/FCF | N/A | ||
| P/OCF | 12.59 | ||
| P/B | 2.43 | ||
| P/tB | 15.92 | ||
| EV/EBITDA | 16.74 |
EPS(TTM)0.65
EY4.39%
EPS(NY)0.92
Fwd EY6.25%
FCF(TTM)-3.28
FCFYN/A
OCF(TTM)1.17
OCFY7.94%
SpS2.65
BVpS6.09
TBVpS0.93
PEG (NY)0.59
PEG (5Y)1.75
Graham Number9.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROCE | 7.18% | ||
| ROIC | 5.17% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 22.78% | ||
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% | ||
| FCFM | N/A |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 1132.75% | ||
| Cap/Sales | 168.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 126.25% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | 5.11 |
F-Score5
WACC7.93%
ROIC/WACC0.65
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%83.33%
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y-12.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year135.95%
EBIT Next 3Y37.58%
EBIT Next 5YN/A
FCF growth 1Y-558.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you provide the ChartMill fundamental rating for CIPHER PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to CPH.CA.
What is the valuation status of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
How profitable is CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 4 / 10.